胰高糖素样肽-1激动剂联合钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病的影响
| 作者: |
1秦律,
1詹晓蓉
1 哈尔滨医科大学附属第一医院内分泌科，哈尔滨 150001 |
| 通讯: |
詹晓蓉
Email: xiaorongzhan@sina.com |
| DOI: | 10.3978/j.issn.2095-6959.2021.01.035 |
摘要
近年来，全球糖尿病患病率逐年增加，其中2型糖尿病(type 2 diabetes mellitus，T2DM)占糖尿病总患病人数的90%~95%。胰高糖素样肽-1(glucagon-like peptide 1，GLP-1)激动剂联合钠-葡萄糖协同转运蛋白2抑制剂(sodium-glucose co-transporter 2 inhibitor，SGLT2)是治疗T2DM的新型降糖药物。本文讨论在给予规范的生活方式(饮食和运动)干预下，GLP-1激动剂联合SGLT2抑制剂对T2DM的安全性和有效性。
关键词：
2型糖尿病；胰高糖素样肽-1激动剂；钠-葡萄糖协同转运蛋白2抑制剂
Effect of glucagon-like peptide 1 receptor agonist combined with sodium-glucose cotransporter 2 inhibitor on type 2 diabetes
CorrespondingAuthor: ZHAN Xiaorong Email: xiaorongzhan@sina.com
DOI: 10.3978/j.issn.2095-6959.2021.01.035
Abstract
In recent years, the global prevalence of diabetes has increased year by year, and type II diabetes mellitus (T2DM) accounts for 90%–95% of the total diabetes cases. Glucagon-like peptide-1 (GLP-1) agonist combined with sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new hypoglycemic drug for T2DM. This article will discuss the safety and efficacy of GLP-1 agonist combined with SGLT2 inhibitor in T2DM under the intervention of standard lifestyle (diet and exercise).
Keywords：
type 2 diabetes; glucagon-like peptide 1 agonist; sodium-glucose cotransporter 2 inhibitor